BRIEF—Mylan and Biocon to present data on biosimilar Herceptin at ASCO 2019

Mylan will present final data from the HERITAGE study of Ogivri, which is under development in collaboration with Biocon Biologics, at the annual meeting of the American Society of Clinical Oncology (ASCO) later this month.

The study compares the product with the reference product, Herceptin (trastuzumab), in certain people with HER2+ metastatic breast cancer.

The firm will present safety and overall survival data, cumulative through 36 months of follow-up, on June 2.

Global biologics head Arnd Annweiler said: "We're pleased with the final results of the landmark HERITAGE study which further validate the safety and efficacy profile of Ogivri and confirm that no clinically meaningful differences exist between the biosimilar product and Herceptin in terms of safety, purity and potency.”